Could Failing Myelin Flexibility Drive Cognitive Decline in Alzheimer’s Disease?

One of the most striking cell-to-cell partnerships in biology may be an overlooked casualty of Alzheimer’s disease. Oligodendrocytes, the glial cells that wrap neuronal axons in insulating sheaths of myelin, have long stood in the shadow of neurons, astrocytes and microglia in dementia research. Yet a new Perspective published in PLOS Biology by Charles ffrench-Constant of the University of East Anglia argues that this neglect may have obscured a crucial piece of the Alzheimer’s puzzle. His proposal centers on a remarkable property of these cells known as adaptive myelination, the ability of the brain to adjust its myelin wiring in response to neural activity throughout life, and the possibility that Alzheimer’s pathology sabotages this process, setting up a vicious cycle that drives cognitive decline.

To appreciate the argument, it helps to understand what myelin actually does. In the central nervous system, oligodendrocytes extend multiple sheet-like processes that spiral around axons, forming the myelin sheaths that enable saltatory conduction, the rapid hopping of electrical signals between gaps called nodes of Ranvier. This architecture does more than speed up transmission; by concentrating voltage-dependent sodium channels at the nodes, it also slashes the energy a neuron spends firing. Beyond electrical insulation, sheaths provide metabolic support, transferring lactate and pyruvate from the sheath to the axon to fuel its energy-hungry activity, and homeostatic support, including protection against damaging oxidants. Myelin, in other words, is not passive wrapping but an active, life-sustaining interface between glia and neurons.

The traditional picture of myelination focuses on white matter, the densely wrapped long-distance cables that connect distant brain regions. But oligodendrocytes and their precursor cells are equally abundant in gray matter, the sparsely myelinated territory of the cortex where information processing actually happens. Detailed reconstructions of mouse cortex have revealed that gray-matter oligodendrocytes often produce sheaths that only partially cover an axon, leaving long naked stretches between them. More striking still, these cells are generated throughout life. New oligodendrocytes keep being born in the adult cortex, and whether they survive and integrate into the circuitry depends directly on neural activity. When mice experience sensory enrichment, for example by having beads hung in their environment, the integration of new oligodendrocytes increases; trim the animals’ whiskers and that effect vanishes.

This activity dependence underpins the concept of adaptive myelination, the idea that the number and size of myelin sheaths can be remodeled by experience. According to this hypothesis, myelin plasticity boosts conduction and refines the synchrony of neural firing, thereby contributing to the long-lasting changes in brain function that we call learning. Experiments in mouse models have repeatedly shown that forming new oligodendrocytes is required for certain forms of learning, lending empirical weight to the concept. Exactly how sparse, isolated sheaths in gray matter enhance circuit performance remains debated. Boosting conduction speed enough to alter synchrony seems intuitively difficult when axons are only intermittently wrapped. But ffrench-Constant points to an equally valid mechanism: even a single internode could deliver the metabolic and homeostatic support that lets a busy axon sustain elevated activity for longer, effectively extending its working endurance.

The evidence that oligodendrocytes matter in Alzheimer’s disease is, by now, substantial. Microstructural abnormalities appear within densely myelinated tracts in affected brains. Gene expression studies show that oligodendrocytes in Alzheimer’s brains enter a disease-associated state, ramping up immune pathways while dialing down the very genes needed for myelination. Genome-wide association studies hunting for Alzheimer’s risk genes have repeatedly flagged genes expressed in oligodendrocytes. The cells also manufacture amyloid-beta themselves, expressing high levels of amyloid precursor protein and the processing enzymes BACE1 and PSEN1. Most compellingly, conditional knockout experiments in Alzheimer’s model mice show that selectively preventing oligodendrocytes from producing amyloid-beta by deleting BACE1 reduces plaque burden by roughly thirty percent, pointing toward a genuinely causal role for these glia in the disease process.

The central question of the Perspective is whether Alzheimer’s-associated changes might block the generation of new oligodendrocytes or new myelin sheaths, thereby disabling adaptive myelination. Several lines of evidence, though indirect, support this possibility. Disease-associated oligodendrocytes downregulate genes in the cholesterol biosynthetic pathway, and since cholesterol is an essential structural component of myelin, this would cripple the cell’s capacity to build new sheaths. Oligodendrocyte precursor cells clustered around amyloid plaques in patient brains display a senescent phenotype expected to inhibit their differentiation into mature myelin-forming cells. And in the hippocampus of rodent Alzheimer’s models, oligodendrocyte numbers fall without any reduction in precursor differentiation, suggesting that newly formed cells are dying at an increased rate. Together, these findings sketch a model in which the Alzheimer’s microenvironment disrupts adaptive myelination in gray matter, depriving active circuits of metabolic and homeostatic support and contributing to the cognitive defects that define the disease.

A crucial feature of this model is its prediction of a feedback loop. Myelination depends on a web of bidirectional physical and biochemical interactions between oligodendrocytes and axons, so a change in one set of interactions rapidly propagates to others. If failing adaptive myelination leaves neurons unable to sustain changes in activity, the resulting neuronal dysfunction and damage would further perturb the signals that normally recruit new oligodendrocytes, deepening the deficit. This cascading failure could help explain why cognitive decline in Alzheimer’s is so relentless, and it suggests that oligodendrocyte pathology need not be the initiating event to become a powerful amplifier of it.

The model also makes a therapeutically encouraging prediction: enhancing oligodendrocyte formation might ameliorate some cognitive defects. Here, the multiple sclerosis field, where promoting remyelination is a major therapeutic goal, offers ready-made strategies. Clemastine, an anti-muscarinic drug known to enhance oligodendrocyte generation and remyelination, improves short-term memory and increases myelin in an Alzheimer’s mouse model. The retinoid X receptor agonist bexarotene likewise improves cognitive loss in a mouse model, although this receptor acts in other relevant cell types such as microglia, so the benefit may not be purely myelin-related. Further studies are clearly warranted, but the prospect of repurposing remyelinating drugs for dementia is an intriguing one.

The Perspective raises deeper questions as well. One concerns the long-observed pattern that brain regions myelinated latest in human development are the first to show neurofibrillary tangles in Alzheimer’s disease. If late-myelinating regions rely more heavily on adaptive myelination than on intrinsic developmental programs, they would be especially vulnerable once that adaptive support fails. Another question touches on the notorious heterogeneity of Alzheimer’s disease. Lessons from multiple sclerosis, where single-cell RNA sequencing reveals that each patient carries a distinct, internally consistent pattern of oligodendrocyte pathology across all their lesions, suggest that Alzheimer’s patients may likewise harbor distinct oligodendrocyte pathways shaped by genotype, including the lipid-delivery defects associated with APOE4, and by confounding pathologies such as neuroinflammation and vascular disease.

That heterogeneity carries a practical warning for clinical trials. If oligodendrocyte-targeted treatments are tested without biomarkers to identify which cellular pathway dominates in each patient, a genuinely effective drug might be discarded simply because its benefit was diluted across patients with fundamentally different pathologies. Avoiding a one-size-fits-all approach, ffrench-Constant argues, will require biomarker studies that stratify patients before trials begin. Whatever the answers to these questions turn out to be, pursuing them promises to illuminate the unique biology of gray-matter oligodendrocytes, a cell type whose lifelong plasticity, metabolic partnership with axons and susceptibility to Alzheimer’s pathology may prove central to understanding, and eventually treating, the cognitive devastation of the disease.

Subject of Research: The potential role of perturbed adaptive myelination by gray-matter oligodendrocytes in Alzheimer's disease cognitive dysfunction

Article Title: Does perturbed adaptive myelination contribute to cognitive dysfunction in Alzheimer’s disease?

Article References: ffrench-Constant, C. (2026). Does perturbed adaptive myelination contribute to cognitive dysfunction in Alzheimer’s disease?. PLOS Biology, 24(10), e3004033. https://doi.org/10.1371/journal.pbio.3004033

Image Credits: AI Generated

DOI: 10.1371/journal.pbio.3004033

Keywords: Alzheimer's disease, oligodendrocytes, adaptive myelination, myelin plasticity, amyloid-beta, gray matter, cognitive dysfunction, remyelination, clemastine, bexarotene, APOE4, neurodegeneration